-
公开(公告)号：EP3417062B1
公开(公告)日：2024-06-26
申请号：EP17753686.9
申请日：2017-02-13
IPC分类号： C12N15/11 , C12N15/113 , C12N9/22 , A61K48/00
-
公开(公告)号：EP3417062A1
公开(公告)日：2018-12-26
申请号：EP17753686.9
申请日：2017-02-13
发明人： KHALILI, Kamel , HU, Wenhui
IPC分类号： C12N15/11 , C12N15/113 , C12N9/22 , A61K48/00
CPC分类号： C12N9/22 , A01K2227/105 , A01K2267/0337 , A61K48/00 , C07K2319/09 , C12N15/1132 , C12N2310/20 , C12N2750/14143
摘要： Compositions for the in vivo delivery of a gene editing CRISPR/Cas9 complex was developed to eliminate integrated retroviral DNA sequences from latently infected human cells and animal disease models
-
公开(公告)号：EP3178943B1
公开(公告)日：2018-10-03
申请号：EP17152888.8
申请日：2014-12-17
申请人： CSIR
IPC分类号： C12N15/113
CPC分类号： C12Q1/6886 , A61K31/197 , A61K31/436 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/475 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/58 , A61K31/675 , A61K31/7072 , A61K31/713 , A61K33/24 , A61K38/12 , C12N15/111 , C12N15/1132 , C12N2310/113 , C12N2310/141 , C12N2320/10 , C12N2320/11 , C12N2320/30 , C12Q1/703 , C12Q2600/136 , C12Q2600/178
摘要： The present invention relates to methods for the identification of anti-HIV miRNAs and anti-HIV pharmaceutical compounds using high-throughput screening methods, comprising: transfecting reporter cells with a panel of miRNAs, infecting the reporter cells with HIV, screening the cells to identify miRNAs that modulate HIV infection and identifying the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs. The invention further provides for the identification and screening of anti-HIV pharmaceutical compounds having known activity against the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs for efficacy in the treatment of HIV. The invention also provides for the use of miRNA mimics, miRNA inhibitors and pharmaceutical compounds (including oncology drugs and kinase inhibitors) in the treatment and/or prevention of HIV infection.
-
公开(公告)号：EP2554550B1
公开(公告)日：2016-09-07
申请号：EP11720370.3
申请日：2011-04-01
发明人： FERNANDEZ ORTEGA, Celia, Berta , RAMÍREZ SUÁREZ, Anna, Caridys , CASILLAS CASANOVA, Dionne , PANEQUE GUERRERO, Taimi, Emelia , UBIETA GÓMEZ, Raimundo , DUBED ECHEVARRÍA, Marta , NAVEA LEYVA, Leonor, Margarita , CASTELLANOS SERRA, Lila, Rosa , DUARTE CANO, Carlos, Antonio , FALCÓN CAMA, Viviana , REYES ACOSTA, Osvaldo
IPC分类号： C07K14/47 , C12N15/113 , A61K31/5575 , A61K38/17 , A61P31/18
CPC分类号： A61K38/10 , A61K31/19 , A61K31/5575 , A61K31/7105 , A61K31/713 , A61K38/1709 , A61K38/1748 , A61K45/06 , C07K14/47 , C07K14/4741 , C12N5/0636 , C12N15/113 , C12N15/1131 , C12N15/1132 , C12N2310/14 , C12N2310/531 , C12N2320/31
-
5.发明公开AUTO -RECOGNIZING THERAPEUTIC RNA/DNA CHIMERIC NANOPARTICLES (NP) 有权THERAPEUTIC嵌合RNA / DNA的纳米颗粒（NP）具有自动检测
公开(公告)号：EP2780455A1
公开(公告)日：2014-09-24
申请号：EP12795973.2
申请日：2012-11-19
发明人： SHAPIRO, Bruce, Allen , AFONIN, Kirill, Andreevich , VIARD, Mathias, Denis , BINDEWALD, Eckart, H.U.
IPC分类号： C12N15/11 , C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1132 , C12N15/1135 , C12N2310/14 , C12N2310/16 , C12N2310/322 , C12N2310/3519 , C12N2320/51 , C12N2310/3533
摘要： Auto-recognizing therapeutic R/DNA chimeric nanoparticles (R/DNA NP) are described that are pairs of DNA/RNA hybrids where the DNA molecules have complementary toehold sequences that promote the re-association of the R/DNA NPs when mixed resulting in the formation of RNA/RNA duplexes that act as siRNAs.
-
公开(公告)号：EP2554550A1
公开(公告)日：2013-02-06
申请号：EP11720370.3
申请日：2011-04-01
发明人： FERNANDEZ ORTEGA, Celia, Berta , RAMÍREZ SUÁREZ, Anna, Caridys , CASILLAS CASANOVA, Dionne , PANEQUE GUERRERO, Taimi, Emelia , UBIETA GÓMEZ, Raimundo , DUBED ECHEVARRÍA, Marta , NAVEA LEYVA, Leonor, Margarita , CASTELLANOS SERRA, Lila, Rosa , DUARTE CANO, Carlos, Antonio , FALCÓN CAMA, Viviana , REYES ACOSTA, Osvaldo
IPC分类号： C07K14/47 , C12N15/113 , A61K31/7105 , A61K38/17 , C07C405/00 , A61K31/5575 , A61P31/18
CPC分类号： A61K38/10 , A61K31/19 , A61K31/5575 , A61K31/7105 , A61K31/713 , A61K38/1709 , A61K38/1748 , A61K45/06 , C07K14/47 , C07K14/4741 , C12N5/0636 , C12N15/113 , C12N15/1131 , C12N15/1132 , C12N2310/14 , C12N2310/531 , C12N2320/31
摘要： The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.
摘要翻译： 本发明通过负调节或改变细胞骨架，更确切地说蛋白质形成中间细胞骨架细丝，worin的所述蛋白质是波形蛋白和/或角蛋白的第十描述抑制人类免疫缺陷病毒（HIV）的复制的方法 病毒的复制是在人细胞中通过蛋白质合成的结构居间抑制。 因此，本发明涉及使用代理，其包含肽和/或干扰RNA和/或脂质化合物，所述试剂产生细胞骨架的负调制或改变，以防止或治疗HIV感染。 本发明提供的手段和用于改变细胞的细胞骨架/长丝结构的方法，其结果是感染人细胞的由HIV受到干扰，甚至可以完全抑制呼叫的结果。 细胞骨架是通过减少波形蛋白和/或角蛋白的量改变（例如，通过使用干扰RNA转录控制）或通过使用肽并扰乱细胞骨架。
-
7.发明授权Oligonucleotides against HIV infection and its application in the prevention and treatment of acquired immune deficiency syndrome 有权抗HIV感染的寡核苷酸及其在预防和治疗获得性免疫缺陷综合征中的应用
公开(公告)号：EP2243786B1
公开(公告)日：2012-08-22
申请号：EP10158895.2
申请日：2003-12-16
发明人： Zhou, Zhiwen , Feng, Yuxia , Zuo, Conglin , Li, Yuejuan
CPC分类号： C12N15/1132 , A61K38/00 , C12N2310/111 , C12N2310/14 , C12N2310/53 , Y02A50/395
摘要： The invention provides a set of nucleotides against HIV infection and their application for treatment and prevention of AIDS. The sequences of the nucleotides were shown in the sequences table. The invention was superior to the similar technology as following: High conserved RNA sequences were obtained by compare all the published HIV genome sequences. Double strand RNA sequences derived from the sequences can effectively inhibit the expression of target HIV gene. HIV gene expression can also be inhibited by double strand hairpin-like RNA transcribed in the cells harboring recombinant plasmid which contain the DNA sequences encoding the RNA sequences. Further, HIV gene expression can be knocked down by in cell transcribed double strand RNA corresponding to the RNA sequences encoded by recombinant adenovirus associated virus.
-
8.发明公开
公开(公告)号：EP2449105A2
公开(公告)日：2012-05-09
申请号：EP10745345.8
申请日：2010-06-28
IPC分类号： C12N15/113 , C07K14/155 , A61K31/713
CPC分类号： C12N15/1137 , C07K14/005 , C12N15/1132 , C12N2310/14 , C12N2310/141 , C12N2320/31 , C12N2740/16222 , C12Y207/07049
摘要： The present invention relates to interfering RNA, in particular miRNAs capable of specifically blocking the replication of an HIV virus strain resistant to an antiretroviral compound, and to the use thereof for treating infections by said type of virus.
-
9.发明授权RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) 有权由RNA介导的抑制丙型肝炎病毒（HCV）基因表达的影响的具有短，扰乱核酸（短干扰核酸，新浪网）的干扰
公开(公告)号：EP1430157B1
公开(公告)日：2011-08-10
申请号：EP03716092.6
申请日：2003-02-20
CPC分类号： C12N15/1132 , A61K38/00 , A61K47/54 , C07H21/02 , C12N15/1131 , C12N15/1137 , C12N15/115 , C12N2310/111 , C12N2310/12 , C12N2310/121 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/318 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/346 , C12N2310/53 , C12Y104/03003 , C12Y114/19001 , C12Y207/07049 , C12Y207/11001 , C12Y207/11013 , C12Y301/03048 , Y02A50/465 , C12N2310/3521
摘要： The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against hepatitis C virus (HCV) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis and any other disease or condition that responds to modulation of HCV expression or activity.
-
公开(公告)号：EP1939290A3
公开(公告)日：2011-07-06
申请号：EP07007057.8
申请日：1994-12-27
申请人： Centre National de la Recherche Scientifique , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , MUSEUM NATIONAL D'HISTOIRE NATURELLE
IPC分类号： C12N15/113 , A61K31/713 , C12N15/86
CPC分类号： C12N15/113 , A61K38/00 , C12N15/1132 , C12N15/1136 , C12N2310/152 , C12N2310/53 , C12N2310/531 , C12N2310/532 , Y10S977/802 , Y10S977/916 , Y10S977/92
摘要： La présente invention concerne de nouveaux vecteurs, les compositions pharmaceutiques les contenant, et leurs utilisations thérapeutiques. Plus particulièrement, elle concerne de nouvelles molécules capables d'agir, de manière très sélective et très efficace, sur l'expression de gènes.
-
-
-
-
-
-
-
-
-
搜索结果
355 条记录 (耗时 0.032 秒)
